JCO Oncol Pract 2022 Jan 07
Q and A: A New Standard of Care for Germline and/or Mutation Carriers With Early-Stage Breast Cancer.
Related Questions
In patients who receive neoadjuvant pembrolizumab and chemotherapy for TNBC, how will you manage adjuvant treatment if they have a germline BRCA mutation?
9
5 Answers
Mednet Member
Medical Oncology · Ohio State University
For patients with clinically high risk early TNBC and germline PV in BRCA 1 or 2 undergoing neoadjuvant chemotherapy along with pembrolizumab, the course of adjuvant therapy will depend on pathologic response at surgery.For those with pCR - I would continue adjuvant pembrolizumab for patients who ar...
How do you sequence capecitabine and olaparib, if at all, in patients with BRCA+ TNBC and residual disease after neoadjuvant chemotherapy?
9
5 AnswersMednet Member
Medical Oncology · Ohio State University
Patients with germline PV in BRCA 1/2 and residual disease following NAC in early TNBC have two options that likely represent standard of care in the adjuvant setting, a) adjuvant capecitabine (CREATE-X, EA1131) and/or b) adjuvant olaparib (NSABP B55). B55 did not allow for any further adjuvant chem...